What this page helps you do
Use this guide to protect a child’s active care in Iraq while preparing a structured pediatric hematology second opinion, guardian documents and the current medical-travel route.
- Before hospital review
- Ask the child’s hematologist to state the confirmed diagnosis, current treatment, transfusion needs, complications and why HSCT or another specialist opinion is being considered.
- Documents
- Provide diagnosis-specific evidence, treatment and transfusion history, recent infection and organ-function results, vaccination records and guardian authorization. Keep originals and translations together.
- Travel with a child
- Turkish visa rules for Iraqi ordinary-passport holders vary by age and supporting status. Applications in Iraq use the currently authorized channel; confirm medical-purpose and accompanying-adult requirements before booking.
- Continuity of care
- Maintain scheduled transfusions, medicines and urgent local care during review. Agree which Iraqi pediatric hematology team will monitor the child after return if treatment proceeds.
- Current pediatric HSCT availability in Iraq could not be verified from a sufficiently current official program source; this evidence gap is not confirmation that the service is absent.
- General entry rules or conditional e-Visa eligibility do not by themselves authorize travel for treatment. Medical-purpose requirements depend on age, passport and individual circumstances and must be reconfirmed through the authorized application channel.
Travel information checked 11 October 2026. Reconfirm requirements before booking.
Pediatric BMT Evaluation in Turkey from Iraq
A parent or legal guardian in Iraq may request a preliminary pediatric specialist review when the child’s treating team is considering HSCT or when the family needs a verified second opinion. Review before travel does not confirm treatment or admission.
Local Pediatric Care in Iraq Remains Essential
Iraq’s Ministry of Health has documented specialist centers caring for children with inherited blood disorders, including thalassemia. Current services, referral capacity and pediatric HSCT availability must be confirmed locally; a cross-border opinion should not interrupt stabilization, transfusions or active treatment.
An international review should complement—not interrupt—the child’s current care in Iraq, especially when treatment or infection management is time-sensitive.
A Blood Disorder Does Not Automatically Mean Transplant
A diagnosis such as leukemia, thalassemia or sickle-cell disease does not by itself mean a child needs transplant. The pediatric hematology team must assess the exact condition, severity, treatment response, alternatives, risks and likely benefit.
Specialists may recommend chemotherapy, transfusion care, medicines, cellular therapy, observation or another approach depending on the case.
Acibadem Altunizade Pediatric Program
Official Acibadem sources connect Altunizade Hospital to adult and pediatric bone marrow transplantation and describe multiple cell-source approaches. It is the published campaign partner, not the only verified program available for comparison.
Potential Donor and HLA Assessment
A sibling, parent or other possible donor is not automatically suitable. HLA matching, donor health, consent, child safeguarding, cell source and any registry or legal requirements need separate specialist review.
Families should not arrange informal donor testing or travel based on assumptions. The transplant center defines the appropriate testing sequence.
Preparing the Child’s Records in Iraq
Organize records around the clinical question and preserve original dates and findings.
- Current pediatric hematology summary and referral question
- Confirmed diagnosis, pathology, marrow and molecular reports
- Treatment, transfusion and chelation history where relevant
- Recent blood counts, infection results and organ-function assessment
- Guardian identity, authorization and accompanying-adult details
- Arabic originals with English or Turkish translations only when requested
- Available HLA or family-donor information only when requested
Parent or Legal-Guardian Submission
A parent or legally authorized guardian can submit the MedTransplant Case Review. The form records who is submitting, their relationship to the child and the authorization required for representation.
From Case Review to Pediatric Team Response
MedTransplant structures the available file and coordinates submission. The hospital may request pathology review, updated testing, HLA information or a pediatric consultation before deciding whether evaluation can progress.
Request Comparison with Other Verified Programs
Families may explore other verified pediatric programs or request comparison through MedTransplant. The comparison does not rank hospitals by unsupported claims and cannot guarantee acceptance.
Planning Travel from Iraq with a Child
Travel should normally follow hospital feedback. Consider the child’s stability, guardian documents, who must accompany the child, requested tests, infection precautions, accommodation and expected stay.
Case-Specific Financial Planning
No unverified package price is presented. If review progresses, costs can depend on diagnostics, donor work-up, cell collection, conditioning, admission and the proposed treatment pathway.
Returning to Pediatric Care in Iraq
Before any treatment, agree how the local pediatric hematology team and the transplant center will communicate about medicines, infections, blood counts, immune recovery, vaccination and urgent concerns.
Continue with the Acibadem Pediatric BMT Guide
Review the partner-program pathway, diagnostic boundaries, donor safeguards and parent or guardian submission process.
Explore pediatric BMT evaluation at Acibadem AltunizadeFrequently Asked Questions
Can a parent submit a child’s case from Iraq?
Yes. A parent or legal guardian can identify their relationship and authorization in the MedTransplant Case Review.
Does leukemia always require bone marrow transplant?
No. Treatment depends on the leukemia type, risk features, response and available alternatives. Pediatric specialists decide whether HSCT should be considered.
Does thalassemia or sickle-cell disease always require transplant?
No. Severity, current treatment, complications, donor options, alternatives and individual risks all matter.
Is a sibling automatically a suitable donor?
No. HLA matching, health, consent, safeguarding and the proposed cell source require separate hospital-led assessment.
Can MedTransplant find a donor?
No. MedTransplant does not find, recruit, sell, broker or guarantee donors.
Does submission guarantee the child’s acceptance?
No. Submission guarantees neither diagnosis, hospital acceptance, donor approval, transplantation, timing nor outcome.
Can families compare another pediatric program?
Yes. Acibadem Altunizade is the published partner for this campaign, while families may explore other verified programs or request comparison.
When should the family book travel?
Usually after the hospital reviews the available file and describes the possible next assessment steps.
Sources and verification
- Acibadem Altunizade Hospital
- Acibadem Pediatric Bone Marrow Transplantation Unit
- NCI: Stem cell and bone marrow transplants
- NCI: Childhood acute lymphoblastic leukemia treatment
- NCI: Children with Cancer—A Guide for Parents
- Iraq Ministry of Health: Care for thalassemia patients at the hereditary blood diseases center
- WHO Iraq country health profile
- Turkish Embassy in Baghdad: Authorized visa application centers from April 2026
- Türkiye Ministry of Foreign Affairs: Visa information for foreigners
- Türkiye Ministry of Foreign Affairs: General information about Turkish visas
Pediatric medical responsibility
MedTransplant coordinates parent- or guardian-led case preparation and referral. Pediatric specialists make all diagnostic, treatment, donor and acceptance decisions.
